{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:03:23Z","timestamp":1794265403013,"version":"4.9.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the increasing prevalence of type 2 diabetes mellitus (T2DM), limited pharmacologic options are available for prevention. Cholesteryl ester transfer protein inhibitors (CETPis) have been studied primarily as a therapy to reduce cardiovascular disease, but have also been shown to reduce new-onset diabetes. As new trial data have become available, this meta-analysis examines the effect of CETP inhibitors on new-onset diabetes and related glycaemic measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We searched MEDLINE, EMBASE, and Cochrane databases (all articles until 4 March, 2021) for randomised controlled trials (RCT)\u00a0\u22651-year duration, with at least 500 participants, comparing CETPi to placebo, and that reported data on new-onset diabetes or related glycaemic measures [haemoglobin A1C (HbA1C), fasting plasma glucose, insulin, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)]. A fixed effects meta-analysis model was applied to all eligible studies to quantify the effect of CETPi therapy on new-onset diabetes. Four RCTs (n\u00a0=\u00a075\u00a0102) were eligible for quantitative analysis of the effect of CETPi on new-onset diabetes. CETPis were found to significantly decrease the risk of new-onset diabetes by 16% (RR: 0.84; 95% CI: 0.78, 0.91; P\u00a0&amp;lt; 0.001), with low between-trial heterogeneity (I2\u00a0=\u00a04.1%). Glycaemic measures were also significantly improved or trended towards improvement in those with and without diabetes across most trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although RCTs have shown mixed results regarding the impact of CETPi on cardiovascular disease, they have shown a consistent reduction in the risk of new-onset diabetes with CETPi therapy. Future trials of CETPis and potentially other HDL-raising agents should therefore specify new-onset diabetes and reversal of existing T2DM as secondary endpoints.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac025","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T11:10:06Z","timestamp":1650280206000},"page":"622-632","source":"Crossref","is-referenced-by-count":46,"title":["The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"given":"Katerina","family":"Dangas","sequence":"first","affiliation":[{"name":"Magdalen College University of Oxford, Oxford , OX1 4AU UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical Center , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J P","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam 1081 , Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"2022120806442839300_bib1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022120806442839300_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2022120806442839300_bib6","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2022120806442839300_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fphar.2015.00258","article-title":"HDL and glucose metabolism: current evidence and therapeutic potential","volume":"6","author":"Siebel","year":"2015","journal-title":"Front Pharmacol"},{"key":"2022120806442839300_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib9","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib13","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","article-title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat Commun"},{"key":"2022120806442839300_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"2022120806442839300_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the women's genome health study","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"2022120806442839300_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrendo.2011.235","article-title":"The emerging role of HDL in glucose metabolism","volume":"8","author":"Drew","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022120806442839300_bib17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","article-title":"High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus","volume":"119","author":"Drew","year":"2009","journal-title":"Circulation"},{"key":"2022120806442839300_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","article-title":"Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk","volume":"44","author":"Masson","year":"2018","journal-title":"Diabetes Metab"},{"key":"2022120806442839300_bib19","doi-asserted-by":"crossref","first-page":"e000943","DOI":"10.1136\/bmjdrc-2019-000943","article-title":"Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial","volume":"8","author":"Menon","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022120806442839300_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2337\/dc19-2204","article-title":"Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease","volume":"43","author":"Schwartz","year":"2020","journal-title":"Diabetes Care"},{"key":"2022120806442839300_bib21","first-page":"390","article-title":"Enhancing retrieval of best evidence for health care from bibliographic databases: calibration of the hand search of the literature","volume":"84","author":"Wilczynski","year":"2001","journal-title":"Stud Health Technol Inform"},{"key":"2022120806442839300_bib22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2022120806442839300_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","article-title":"Effect of torcetrapib on glucose, insulin, and haemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial","volume":"124","author":"Barter","year":"2011","journal-title":"Circulation"},{"key":"2022120806442839300_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/heartjnl-2015-308055","article-title":"Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials","volume":"102","author":"Goldie","year":"2016","journal-title":"Heart"},{"key":"2022120806442839300_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOL.0b013e328350fad2","article-title":"Finding genes and variants for lipid levels after genome-wide association analysis","volume":"23","author":"Willer","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"2022120806442839300_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.numecd.2009.06.009","article-title":"Association of taq 1B CETP polymorphism with insulin and HOMA levels in the population of the canary islands","volume":"21","author":"L\u00f3pez-R\u00edos","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022120806442839300_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199801083380203","article-title":"The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group","volume":"338","author":"Kuivenhoven","year":"1998","journal-title":"N Engl J Med"},{"key":"2022120806442839300_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.atherosclerosis.2015.08.015","article-title":"Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease","volume":"242","author":"Koopal","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022120806442839300_bib30","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/ATVBAHA.110.207373","article-title":"Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion","volume":"30","author":"Fryirs","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022120806442839300_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1194\/jlr.RA119000509","article-title":"HDL inhibits endoplasmic reticulum stress-induced apoptosis of pancreatic \u03b2-cells in vitro by activation of smoothened","volume":"61","author":"Yalcinkaya","year":"2020","journal-title":"J Lipid Res"},{"key":"2022120806442839300_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MOL.0b013e328339387b","article-title":"HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus","volume":"21","author":"Kruit","year":"2010","journal-title":"Curr Opin Lipidol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac025\/45033496\/pvac025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/6\/622\/47715481\/pvac025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/6\/622\/47715481\/pvac025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T06:44:54Z","timestamp":1670481894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/6\/622\/6571249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2022,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac025","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,4,20]]}}}